Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Holding INMB?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.56Last Year’s EPS
-$0.47Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -24.79%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in clinical trial progress and financial stability outweighing the increased net loss and R&D expenses. The company's strategic focus on advancing its Alzheimer's and cancer programs shows promise for future developments.Company Guidance
During INmune Bio's Q3 2024 earnings call, several key metrics and milestones were discussed. The company closed enrollment for the ADO2 Phase II trial of XPro in Alzheimer's disease patients on September 27, with data expected in Q2 2025. Additionally, they are progressing with their INKmune program for metastatic castrate-resistant prostate cancer, with the first patient in the high-dose cohort having received treatment on November 5, 2024. Financially, INmune Bio raised $13 million in gross proceeds during the quarter, ending with $33.6 million in cash, sufficient to fund operations into Q3 2025. The company's net loss was approximately $12.1 million, up from $8.6 million the previous year, with R&D expenses also increasing from $6 million to $10.1 million. The call highlighted the company's commitment to advancing its clinical programs while maintaining strong financial management.Completion of Enrollment in Alzheimer's Phase II Trial
INmune Bio successfully closed enrollment for the ADO2 Phase II trial of XPro for Alzheimer's disease on September 27, a significant milestone indicating progress in their most advanced program.
Progress in INKmune Cancer Program
The INKmune program for metastatic castrate-resistant prostate cancer has enrolled its first patient in the highest dose cohort, showing consistent immunologic effects and maintaining a strong safety profile.
Strong Financial Position
INmune Bio raised $13 million in gross proceeds from a registered direct equity offering, ensuring sufficient funding for operations into Q3 2025.
Upcoming Alzheimer's and Depression Trials
INmune Bio is set to initiate a Phase II trial for treatment-resistant depression by the end of the year, with anticipated top-line cognitive data from the Alzheimer's Phase II trial expected in Q2 2025.
---
INMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $5.85 | $6.04 | +3.25% |
| Aug 01, 2024 | $7.91 | $8.17 | +3.29% |
| May 09, 2024 | $10.77 | $10.02 | -6.96% |
| Mar 28, 2024 | $11.75 | $11.52 | -1.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inmune Bio Inc (INMB) report earnings?
Inmune Bio Inc (INMB) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Inmune Bio Inc (INMB) earnings time?
Inmune Bio Inc (INMB) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMB EPS forecast?
INMB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.56.
---